Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Analysts

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $5.17.

SGMO has been the topic of several recent analyst reports. StockNews.com cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Truist Financial reduced their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Monday, January 27th. Wells Fargo & Company reduced their price target on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 31st. Finally, Jefferies Financial Group cut their target price on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, December 31st.

Sangamo Therapeutics Stock Performance

SGMO stock opened at $0.84 on Friday. The company has a market capitalization of $175.08 million, a P/E ratio of -1.12 and a beta of 1.49. Sangamo Therapeutics has a 52-week low of $0.30 and a 52-week high of $3.18. The business has a 50-day simple moving average of $1.07 and a two-hundred day simple moving average of $1.40.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The firm had revenue of $7.55 million for the quarter, compared to the consensus estimate of $11.70 million. As a group, sell-side analysts forecast that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutional Trading of Sangamo Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC raised its stake in shares of Sangamo Therapeutics by 12.4% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 122,463 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 13,518 shares during the last quarter. Jefferies Financial Group Inc. bought a new position in Sangamo Therapeutics in the fourth quarter worth about $55,000. Two Sigma Advisers LP bought a new position in Sangamo Therapeutics in the fourth quarter worth about $722,000. Two Sigma Investments LP raised its stake in Sangamo Therapeutics by 222.1% in the fourth quarter. Two Sigma Investments LP now owns 1,012,640 shares of the biopharmaceutical company’s stock worth $1,033,000 after buying an additional 698,296 shares in the last quarter. Finally, Rafferty Asset Management LLC purchased a new stake in Sangamo Therapeutics in the fourth quarter worth about $358,000. 56.93% of the stock is owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.